GlassScriptPhysician profile
Gregory T Hofeldt
NPI 1497771943
$2,428.78
in general payments reported to CMS, 2019-2025
23 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $72.53 · 2021: $117 · 2022: $367 · 2023: $458 · 2024: $404 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $648.93 | 2019-2025 | Clareon Panoptix Pro, Clareon, Argos |
| Novartis Pharmaceuticals Corporation | $368.94 | 2019-2023 | |
| New World Medical,INC. | $347.98 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Abbvie INC. | $151.71 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $146.13 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $144.99 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $137.08 | 2025 | |
| Apellis Pharmaceuticals, INC. | $90.42 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $63.89 | 2019-2021 | |
| Allergan, INC. | $39.99 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $37.01 | 2022 | |
| Horizon Therapeutics Plc | $33.13 | 2022 | |
| Dompe US, INC. | $31.66 | 2025 | Oxervate |
| Optos, INC. | $28.41 | 2020 | |
| Dusa Pharmaceuticals, INC. | $25.79 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $24.07 | 2019 | |
| Amgen INC. | $22.30 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $18.79 | 2024 | Xdemvy |
| Shire North American Group INC | $15.65 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $14.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.13 | 2022 | |
| Ocular Therapeutix, INC. | $12.31 | 2021 | |
| Optovue, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Hofeldt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.